Affiliation:
1. Departments of Medicine and Family Medicine University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA
2. Jordan University of Science and Technology Faculty of Pharmacy Irbid Jordan
3. Martha S. Pitzer Center for Women, Children and Youth The Ohio State University College of Nursing Columbus Ohio USA
4. Department of Health Policy Vanderbilt University School of Medicine Nashville Tennessee USA
Abstract
AbstractBackgroundMultiple factors, such as less complex U.S. adult pneumococcal recommendations that could increase vaccination rates, childhood pneumococcal vaccination indirect effects that decrease adult vaccination impact, and increased vaccine hesitancy (particularly in underserved minorities), could diminish the cost‐effectiveness of programs to increase pneumococcal vaccination in older adults. Prior analyses supported the economic favorability of these programs.MethodsA Markov model compared no vaccination and current recommendations (either 20‐valent pneumococcal conjugate vaccine [PCV20] alone or 15‐valent pneumococcal conjugate vaccine plus the 23‐valent pneumococcal polysaccharide vaccine [PCV15/PPSV23]) without or with programs to increase vaccine uptake in Black and non‐Black 65‐year‐old cohorts. Pre‐pandemic population‐ and serotype‐specific pneumococcal disease risk and illness/vaccine costs came from U.S. databases. Program costs were $2.19 per vaccine‐eligible person and increased absolute vaccination likelihood by 7.5%. Delphi panel estimates and trial data informed vaccine effectiveness values. Analyses took a healthcare perspective, discounting at 3%/year over a lifetime time horizon.ResultsUptake programs decreased pneumococcal disease overall. In Black cohorts, PCV20 without program cost $216,805 per quality‐adjusted life year (QALY) gained compared with no vaccination; incremental cost‐effectiveness was $245,546/QALY for PCV20 with program and $425,264/QALY for PCV15/PPSV23 with program. In non‐Black cohorts, all strategies cost >$200,000/QALY gained. When considering the potential indirect effects from childhood vaccination, all strategies became less economically attractive. Increased vaccination with less complex strategies had negligible effects. In probabilistic sensitivity analyses, current recommendations with or without programs were unlikely to be favored at thresholds <$200,000/QALY gained.ConclusionCurrent U.S. pneumococcal vaccination recommendations for older adults were unlikely to be economically reasonable with or without programs to increase vaccine uptake. Alternatives to current pneumococcal vaccines that include pneumococcal serotypes associated with adult disease should be considered.
Funder
National Institute of Allergy and Infectious Diseases
Reference31 articles.
1. College of Physicians of Philadelphia.History of Vaccines: Pneumonia (Pneumococcal Disease).https://historyofvaccines.org/diseases/pneumonia-pneumococcal-diseaseAccessed May 2023.
2. National Center for Immunization and Respiratory Diseases.Centers for Disease Control and Prevention. Pneumococcal Disease Surveillance and Reporting. https://www.cdc.gov/pneumococcal/surveillance.html#:~:text=Invasive%20pneumococcal%20disease%20caused%20by%20the%2013%20serotypes%20included%20in per%20100%2C000%20people%20in%202019 Accessed June 9 2023.
3. Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults
4. Pneumococcal vaccination in older adults: An initial analysis of social determinants of health and vaccine uptake
5. Barriers of Influenza Vaccination Intention and Behavior – A Systematic Review of Influenza Vaccine Hesitancy, 2005 – 2016
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献